Be the first person to write a business review for Oxford Therapeutics Consulting Limited

OXiGENE, Inc. company was founded in 1988 and is headquartered in Waltham, Massachusetts. OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology.

Pacific Biosciences, Inc. company was founded in 2004 and is based in Menlo Park, California. Pacific Biosciences, Inc. operates as a biotechnology company in North America. The company develops a transformative single-molecule (SMRT) DNA sequencing platform, which enables the observation of natural DNA synthesis by a DNA polymerase as it occurs; simplifies the resequencing of complex genomes; and the characterization of structural variation, including insertions, deletions, and rearrangements. Its products include SMRT chip, which enables the observation of individual fluorophores against a dense background of labeled nucleotides by maintaining a signal-to-noise ratio; and Phospholinked nucleotides that produce a natural DNA strand through DNA synthesis. Its product applications include de novo sequencing and resequencing. Pacific Biosciences, Inc. was formerly known as Nanofluidics, Inc.

Panacea Pharmaceuticals, Inc. was founded in 1999 and is based in Gaithersburg, Maryland. Panacea Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic and diagnostic products for cancer and diseases of the central nervous system. It focuses on the development of proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. The company’s products include PAN-22, a human anit-HAAH monoclonal antibody for treatment of hepatocellular carcinoma; PAN-622, a Toxin Conjugate to treat carcinoma of the bile duct; and PAN-811 for the treatment of ischemic stroke. In addition, it develops blood, serum, and tissue tests to diagnose and monitor breast, colorectal, lung, and prostate cancers, as well as gene expression test that predicts the response of patients with Chronic Myelogenous Leukemia to imatinib.

Pathwork Diagnostics is hoping to offer doctors the ability to predict which diseases a patient may have. The company is developing methods to identify biomarker patterns that indicate certain types of diseases. Many tests cannot identify diseases in their early forms. Pathwork Diagnostics is working on identifying the earliest possible signs of a given disease, such as cancer, to help doctors determine the best therapies to treat that disease. The company was founded in 2002. Investment firms Advent Venture, Prospect Venture, and Versant Ventures are the largest shareholders.

PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company licenses its technologies to make and sell antibodies that bind to respiratory syncytial virus, as well as antibodies that bind to the alpha subunit of the VLA-4 integrin. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.